Assessment and management of methotrexate hepatotoxicity in psoriasis patients: Report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 7, 2011, Pages 758-764

  Barker, J ^a   Horn, E J ^b   Lebwohl, M ^c   Warren, R B ^d   Nast, A ^e   Rosenberg, W ^f   Smith, C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b International Psoriasis Council   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Drug toxicity; Hepatotoxicity; Methotrexate; Pharmacogenetics; Pharmacokinetics; Pharmacological biomarkers; Psoriasis

Indexed keywords

ABC TRANSPORTER; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ELECTROLYTE; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; GELATINASE A; GLYCOPROTEIN GP 39; HAPTOGLOBIN; LACTATE DEHYDROGENASE; LAMININ; LIVER ENZYME; METHOTREXATE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROTEIN; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNDULIN; UREA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BIOPSY; BLOOD CELL COUNT; BONE MARROW TOXICITY; CLINICAL ASSESSMENT; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLIC ACID DEFICIENCY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC ASSOCIATION; HEPATITIS B; HEPATITIS C; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER TOXICITY; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; THORAX RADIOGRAPHY; URINE SEDIMENT;

BIOLOGICAL MARKERS; DERMATOLOGIC AGENTS; DIETARY SUPPLEMENTS; DRUG-INDUCED LIVER INJURY; FOLIC ACID; HUMANS; LIVER; METHOTREXATE; PHARMACOGENETICS; PSORIASIS; RISK FACTORS;

EID: 79959814037     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03932.x     Document Type: Review

References (48)

1. Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658-665. (Pubitemid 36975998)
2. Flytstrom I, Stenberg B, Svensson A et al. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116-121. (Pubitemid 350221914)
3. Edmundson WF, Guy WB. Treatment of psoriasis with folic acid antagonists. AMA Arch Derm 1958; 78: 200-203.
4. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 711-716.
5. Gutierrez-Urena S, Molina JF, Garcia CO et al. Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 272-276. (Pubitemid 26065267)
6. Chakravarty K, McDonald H, Pullar T et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford) 2008; 47: 924-925.
7. Spuls PI, Tuut MK, van Everdingen JJ et al. The practice guideline 'Photo(chemo)therapy and systemic therapy in severe chronic plaquepsoriasis'. Ned Tijdschr Geneeskd 2004; 148: 2121-2125. (Pubitemid 39433782)
8. Berends MA, de Jong EM, van de Kerkhof PC et al. Dermatologists' adherence to the guideline of the Dutch Society of Dermatology and Venereology with respect to the treatment with methotrexate for severe chronic plaque psoriasis: results from a Dutch survey. Dermatology 2007; 215: 45-52. (Pubitemid 46976014)
9. Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl. 2): 1-70.
10. Nast A, Kopp I, Augustin M et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007; 299: 111-138. (Pubitemid 46835379)
11. Nast A, Kopp IB, Augustin M et al. S3-Guidelines for the therapy of psoriasis vulgaris. J Dtsch Dermatol Ges 2006; 4(Suppl. 2): S1-S126.
12. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19: 145-156.
13. Menter A, Korman NJ, Elmets CA et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451-485.
14. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38: 478-485. (Pubitemid 28125534)
15. Kalb RE, Strober B, Weinstein G et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60: 824-837.
16. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-469. (Pubitemid 23075264)
17. van Ede AE, Laan RF, Rood MJ et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, doubleblind, placebo-controlled study. Arthritis Rheum 2001; 44: 1515-1524. (Pubitemid 32651731)
18. Casserly CM, Stange KC, Chren MM. Severe megaloblastic anemia in a patient receiving low-dose methotrexate for psoriasis. J Am Acad Dermatol 1993; 29: 477-480. (Pubitemid 23260140)
19. Ilan Y. Review article: the assessment of liver function using breath tests. Aliment Pharmacol Ther 2007; 26: 1293-1302. (Pubitemid 350045611)
20. Ashton RE, Millward-Sadler GH, White JE. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis. J Invest Dermatol 1982; 79: 229-232. (Pubitemid 12033932)
21. Rosenberg P, Urwitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111-1118. (Pubitemid 46669734)
22. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
23. Wolf R, Wolf D, Ruocco V. Alcohol intake and psoriasis. Clin Dermatol 1999; 17: 423-430. (Pubitemid 29412935)
24. McGill DB, Rakela J, Zinsmeister AR et al. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology 1990; 99: 1396-1400. (Pubitemid 20381876)
25. Rousselet MC, Michalak S, Dupre F et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41: 257-264. (Pubitemid 40165369)
26. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457. (Pubitemid 37466971)
27. Ratziu V, Charlotte F, Heurtier A et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005; 128: 1898-1906. (Pubitemid 40824701)
28. Friedrich-Rust M, Ong MF, Herrmann E et al. Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007; 188: 758-764.
29. Rettenbacher T. Focal liver lesions: role of contrast-enhanced ultrasound. Eur J Radiol 2007; 64: 173-182. (Pubitemid 47588758)
30. Gebo KA, Herlong HF, Torbenson MS et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatology 2002; 36: S161-S172. (Pubitemid 35253477)
31. Rosenberg WM, Voelker M, Thiel R et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004; 127: 1704-1713. (Pubitemid 39575849)
32. Guha IN, Parkes J, Roderick P et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008; 47: 455-460. (Pubitemid 351280713)
33. Mayo MJ, Parkes J, Adams-Huet B et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48: 1549-1557.
34. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005; 152: 444-450. (Pubitemid 40547117)
35. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest 1985; 76: 907-912.
36. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-2774. (Pubitemid 39209513)
37. Stamp LK, O'Donnell JL, Chapman PT et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-368.
38. Hroch M, Chladek J, Simkova M et al. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment. J Eur Acad Dermatol Venereol 2008; 22: 19-24.
39. Hoekstra M, Haagsma C, Neef C et al. Splitting high-dose oral methotrexate improves bioavailability: a pharmacokinetic study in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 481-485. (Pubitemid 43334568)
40. Braun J, Kastner P, Flaxenberg P et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008; 58: 73-81.
41. Wegrzyn J, Adeleine P, Miossec P. Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1232-1234. (Pubitemid 39273499)
42. Stamp L, Roberts R, Kennedy M et al. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed Pharmacother 2006; 60: 678-687.
43. Dalrymple JM, Stamp LK, O'Donnell JL et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-3308.
44. Brooks AJ, Begg EJ, Zhang M et al. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther Drug Monit 2007; 29: 619-625. (Pubitemid 47494061)
45. Chladek J, Simkova M, Vaneckova J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008; 64: 347-355.
46. Campalani E, Arenas M, Marinaki AM et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127: 1860-1867. (Pubitemid 47075365)
47. Warren RB, Smith RL, Campalani E et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438-441.
48. Warren RB, Smith RL, Campalani E et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925-1929. (Pubitemid 352001201)